Refine
Year of publication
Document Type
- Article (34)
- Conference Proceeding (1)
Language
- English (35)
Has Fulltext
- yes (35)
Is part of the Bibliography
- no (35)
Keywords
- glioblastoma (9)
- hypoxia (4)
- Glioblastoma (3)
- mTOR (3)
- EGFR (2)
- Fasting (2)
- Glucose (2)
- Ketogenic diet (2)
- Leptin (2)
- MRI (2)
- Radiation (2)
- Targeted therapy (2)
- brain metastases (2)
- brain metastasis (2)
- glioma (2)
- meningioma (2)
- metabolism (2)
- mitochondria (2)
- starvation (2)
- tumor microenvironment (2)
- 2-deoxyglucose (2-DG) (1)
- 4-1BB (1)
- Addison’s disease (1)
- Astrocytoma (1)
- BRAF (1)
- BRAF V600E (1)
- Bevacizumab (1)
- Biomarker (1)
- Brain metastasis (1)
- Brain tumor (1)
- CD137 (1)
- CD74 (1)
- CPE (1)
- Cancer (1)
- Cell biology (1)
- DDIT4 (1)
- DNA methylation (1)
- Dexamethasone (1)
- EGFRvIII mutation (1)
- Edema (1)
- Epidermal growth factor receptor (1)
- Glioma (1)
- Grading (1)
- HLA class II (1)
- HLA peptidome (1)
- IDH mutation (1)
- KPS (1)
- LC3B (1)
- Low grade glioma (1)
- MRI patterns of gliomas (1)
- Malignant meningioma (1)
- Mammalian target of rapamycin (1)
- Meningioma (1)
- Molecular matched therapy (1)
- Molecular profiling (1)
- NSCLC (1)
- Neuropilin (1)
- Nimotuzumab (1)
- Oligodendroglioma (1)
- PD-1 (1)
- PD-L1 (1)
- PML (1)
- PXA (1)
- Radiation necrosis (1)
- SKALE score (1)
- Side effect (1)
- Temozolomide (1)
- Tet-inducible system (1)
- Treatment outcome (1)
- Tumor infiltrating lymphocytes (1)
- VEGF (1)
- VEGF receptors (1)
- Warburg effect (1)
- adrenal insuffciency (1)
- anaemia (1)
- anticonvulsant (1)
- antiepileptic drug (1)
- apoptosis (1)
- astrocytoma (1)
- autophagy (1)
- bevacizumab (1)
- biomarker (1)
- cerebral pseudoprogression (1)
- cerebral radiation necrosis (1)
- cetuximab-bevacizumab therapy sequence (1)
- colon carcinoma (1)
- dabrafenib (1)
- doxycycline (1)
- elderly (1)
- epidermal growth factor receptor (1)
- epilepsy (1)
- glycolysis (1)
- hypoxia-induced cell death (1)
- immune checkpoint inhibitors (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immune response (1)
- immunotherapy (1)
- inducible gene expression (1)
- isocaloric ketogenic diet (1)
- leptomeningeal disease (1)
- mTOR inhibition (1)
- malignant glioma (1)
- melanoma (1)
- metabolic cancer therapy (1)
- migration (1)
- neoadjuvant immunochemotherapy (1)
- neuroimaging (1)
- neurological complication (1)
- neurological side effects (1)
- patterns of progression (1)
- pembrolizumab (1)
- perioperative ischemia (1)
- pleomorphic xanthoastrocytoma (1)
- red blood cells (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- seizure (1)
- stereotactic radiosurgery (1)
- tetracycline (1)
- transfusion (1)
- tumor metabolism (1)
- tumor necrosis factor receptor superfamily member 9 (1)
- tumor-infiltrating lymphocytes (1)
- vascular endothelial growth factor receptor (1)
Institute
Immunohistochemical assessment of phosphorylated mTORC1-pathway proteins in human brain tumors
(2015)
Background: Current pathological diagnostics include the analysis of (epi-)genetic alterations as well as oncogenic pathways. Deregulated mammalian target of rapamycin complex 1 (mTORC1) signaling has been implicated in a variety of cancers including malignant gliomas and is considered a promising target in cancer treatment. Monitoring of mTORC1 activity before and during inhibitor therapy is essential. The aim of our study is to provide a recommendation and report on pitfalls in the use of phospho-specific antibodies against mTORC1-targets phospho-RPS6 (Ser235/236; Ser240/244) and phospho-4EBP1 (Thr37/46) in formalin fixed, paraffin embedded material.
Methods and findings: Primary, established cell lines and brain tumor tissue from routine diagnostics were assessed by immunocyto-, immunohistochemistry, immunofluorescent stainings and immunoblotting. For validation of results, immunoblotting experiments were performed. mTORC-pathway activation was pharmacologically inhibited by torin2 and rapamycin. Torin2 treatment led to a strong reduction of signal intensity and frequency of all tested antibodies. In contrast phospho-4EBP1 did not show considerable reduction in staining intensity after rapamycin treatment, while immunocytochemistry with both phospho-RPS6-specific antibodies showed a reduced signal compared to controls. Staining intensity of both phospho-RPS6-specific antibodies did not show considerable decrease in stability in a timeline from 0–230 minutes without tissue fixation, however we observed a strong decrease of staining intensity in phospho-4EBP1 after 30 minutes. Detection of phospho-signals was strongly dependent on tissue size and fixation gradient. mTORC1-signaling was significantly induced in glioblastomas although not restricted to cancer cells but also detectable in non-neoplastic cells.
Conclusion: Here we provide a recommendation for phospho-specific immunohistochemistry for patient-orientated therapy decisions and monitoring treatment response.
Simple cells in primary visual cortex were famously found to respond to low-level image components such as edges. Sparse coding and independent component analysis (ICA) emerged as the standard computational models for simple cell coding because they linked their receptive fields to the statistics of visual stimuli. However, a salient feature of image statistics, occlusions of image components, is not considered by these models. Here we ask if occlusions have an effect on the predicted shapes of simple cell receptive fields. We use a comparative approach to answer this question and investigate two models for simple cells: a standard linear model and an occlusive model. For both models we simultaneously estimate optimal receptive fields, sparsity and stimulus noise. The two models are identical except for their component superposition assumption. We find the image encoding and receptive fields predicted by the models to differ significantly. While both models predict many Gabor-like fields, the occlusive model predicts a much sparser encoding and high percentages of ‘globular’ receptive fields. This relatively new center-surround type of simple cell response is observed since reverse correlation is used in experimental studies. While high percentages of ‘globular’ fields can be obtained using specific choices of sparsity and overcompleteness in linear sparse coding, no or only low proportions are reported in the vast majority of studies on linear models (including all ICA models). Likewise, for the here investigated linear model and optimal sparsity, only low proportions of ‘globular’ fields are observed. In comparison, the occlusive model robustly infers high proportions and can match the experimentally observed high proportions of ‘globular’ fields well. Our computational study, therefore, suggests that ‘globular’ fields may be evidence for an optimal encoding of visual occlusions in primary visual cortex.
Background: Hypoxia is a key driver for infiltrative growth in experimental gliomas. It has remained elusive whether tumor hypoxia in glioblastoma patients contributes to distant or diffuse recurrences. We therefore investigated the influence of perioperative cerebral ischemia on patterns of progression in glioblastoma patients.
Methods: We retrospectively screened MRI scans of 245 patients with newly diagnosed glioblastoma undergoing resection for perioperative ischemia near the resection cavity. 46 showed relevant ischemia nearby the resection cavity. A control cohort without perioperative ischemia was generated by a 1:1 matching using an algorithm based on gender, age and adjuvant treatment. Both cohorts were analyzed for patterns of progression by a blinded neuroradiologist.
Results: The percentage of diffuse or distant recurrences at first relapse was significantly higher in the cohort with perioperative ischemia (61.1%) compared to the control cohort (19.4%). The results of the control cohort matched well with historical data. The change in patterns of progression was not associated with a difference in survival.
Conclusions: This study reveals an unrecognized association of perioperative cerebral ischemia with distant or diffuse recurrence in glioblastoma. It is the first clinical study supporting the concept that hypoxia is a key driver of infiltrative tumor growth in glioblastoma patients.
Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic acid
(2014)
B10 is a glycosylated derivative of betulinic acid with promising activity against glioma cells. Lysosomal cell death pathways appear to be essential for its cytotoxicity. We investigated the influence of hypoxia, nutrient deprivation and current standard therapies on B10 cytotoxicity. The human glioma cell lines LN-308 and LNT-229 were exposed to B10 alone or together with irradiation, temozolomide, nutrient deprivation or hypoxia. Cell growth and viability were evaluated by crystal violet staining, clonogenicity assays, propidium iodide uptake and LDH release assays. Cell death was examined using an inhibitor of lysosomal acidification (bafilomycin A1), a cathepsin inhibitor (CA074-Me) and a short-hairpin RNA targeting cathepsin B. Hypoxia substantially enhanced B10-induced cell death. This effect was sensitive to bafilomycin A1 and thus dependent on hypoxia-induced lysosomal acidification. Cathepsin B appeared to mediate cell death because either the inhibitor CA074-Me or cathepsin B gene silencing rescued glioma cells from B10 toxicity under hypoxia. B10 is a novel antitumor agent with substantially enhanced cytotoxicity under hypoxia conferred by increased lysosomal cell death pathway activation. Given the importance of hypoxia for therapy resistance, malignant progression, and as a result of antiangiogenic therapies, B10 might be a promising strategy for hypoxic tumors like malignant glioma.
Aim: The cytokine receptor tumor necrosis factor receptor superfamily member 9 (TNFRSF9) is mainly considered to be a co-stimulatory activation marker in hematopoietic cells. Several preclinical models have shown a dramatic beneficial effect of treatment approaches targeting TNFRSF9 with agonistic antibodies. However, preliminary clinical phase I/II studies were stopped after the occurrence of several severe deleterious side effects. In a previous study, it was demonstrated that TNFRSF9 was strongly expressed by reactive astrocytes in primary central nervous system (CNS) tumors, but was largely absent from tumor or inflammatory cells. The aim of the present study was to address the cellular source of TNFRSF9 expression in the setting of human melanoma brain metastasis, a highly immunogenic tumor with a prominent tropism to the CNS.
Methods: Melanoma brain metastasis was analyzed in a cohort of 78 patients by immunohistochemistry for TNFRSF9 and its expression was correlated with clinicopathological parameters including sex, age, survival, tumor size, number of tumor spots, and BRAF V600E expression status.
Results: Tumor necrosis factor receptor superfamily member 9 was frequently expressed independently on both melanoma and endothelial cells. In addition, TNFRSF9 was also present on smooth muscle cells of larger vessels and on a subset of lymphomonocytic tumor infiltrates. No association between TNFRSF9 expression and patient survival or other clinicopathological parameters was seen. Of note, several cases showed a gradual increase in TNFRSF9 expression on tumor cells with increasing distance from blood vessels, an observation that might be linked to hypoxia-driven TNFRSF9 expression in tumor cells.
Conclusion: The findings indicate that the cellular source of TNFRSF9 in melanoma brain metastasis largely exceeds the lymphomonocytic pool, and therefore further careful (re-) assessment of potential TNFRSF9 functions in cell types other than hematopoietic cells is needed. Furthermore, the hypothesis of hypoxia-driven TNFRSF9 expression in brain metastasis melanoma cells requires further functional testing.